Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q4 2023 Earnings Call Transcript

Oleksy Soroka: Okay, all right. Thank you.

Richard Francis: Thanks Oleksy, thanks for the question.

Operator: Thank you. Our next question comes from Madison Aron from JP Morgan. Your line is now open, please go ahead.

Madison Aron: Hi, thanks for taking my question. On your Page 14 on the generic pipeline, you include Nexplanon as one of your technology targets. Can you just walk us through as to what you’re planning there? Is that an ANDA filing that you’re planning? Just if you could give us some detail, thank you.

Richard Francis: Hi Madison, thanks for the question. I’m glad you noticed Slide 14 and the numerous complex generics we’re bringing to the market. With regard to some of these, obviously it’s quite a competitive environment, so we don’t like to go into too much of the specifics because of the nature of that. I think highlighting them gives a good insight to what we have and what’s coming, and I think that’s what we wanted to show here and the fact that we have a very broad portfolio across a number of technologies, so that’s our aim here. But for competitive reasons, we really don’t want to get into the strategy and the details around that, and hopefully you can understand that.

Madison Aron: Thank you.

Operator: Thank you. At this time, we currently have no further questions, so I’ll hand back to Richard Francis for any further remarks.

Richard Francis: Thank you, and thank you everybody for dialing in. I appreciate your interest in Teva and I appreciate the questions, and I look forward to catching up with many of you in the next couple of days and obviously look forward to speaking to you at quarter one earnings later in the year. Thank you very much.

Operator: Thank you for joining today’s call. You may now disconnect your lines.